Pulmonx Corp. (LUNG) - Q1 2026 10-Q Summary
Business Context and Reporting Period
Pulmonx Corporation is a commercial-stage medical technology company providing minimally invasive treatments for severe emphyma, primarily through its Zephyr Endobronchial Valve. This report covers the quarterly period ended March 31, 2026. The Company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $20.6 million | $22.5 million |
| Gross Profit | $16.0 million | $16.3 million |
| Gross Margin | 77.9% | 72.5% |
| Net Loss | $(13.7) million | $(14.4) million |
| Diluted EPS | $(0.33) | $(0.36) |
| Cash and Equivalents | $61.6 million | $74.6 million |
| Operating Cash Flow | $(10.1) million | $(13.2) million |
| Total Debt (Net) | $37.3 million | $37.0 million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 8.7% year-over-year. The decline was driven by a lack of sales into China while awaiting registration certificate renewal and a decrease in international sales volume.
- Margin Expansion: Gross margin improved to 77.9% from 72.5%, primarily due to a favorable geographic mix and lower manufacturing costs relative to volume.
- Debt Restructuring: In March 2026, the Company repaid its entire CIBC Loan obligation ($37.2 million) and entered into a new $60.0 million senior secured term loan facility with Perceptive Credit Holdings V, LP ("Perceptive Loan"), initially drawing $40.0 million.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 7.8% due to reduced advertising, marketing, and travel costs.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing cash ($61.6 million) is sufficient to fund operations for at least the next 12 months. The Company expects to continue incurring net losses as it invests in sales, marketing, and R&D.
- Debt Covenants: The new Perceptive Loan includes financial covenants requiring minimum unrestricted cash of $4.0 million and specific consolidated revenue thresholds. Additional tranches of up to $20.0 million are available upon meeting revenue milestones of $92.5 million and $100.0 million in trailing twelve-month periods.
- Legal Resolution: A Qui Tam action (False Claims Act investigation) initiated in 2022 was settled and dismissed in December 2025.
- Key Risks: Significant risks include reliance on a single product (Zephyr Valve), reimbursement challenges, regulatory approvals for new products (AeriSeal System), and the impact of trade policies/tariffs on supply chain costs.
Investor Verification Checklist
- China Market Status: Verify the timeline for the renewal of the registration certificate in China, as this was the primary driver of the revenue decline.
- Debt Service Capacity: Assess the Company's ability to meet the revenue covenants ($92.5M and $100M TTM) required to access the remaining $20M of the Perceptive Loan facility.
- Reimbursement Trends: Monitor updates on Medicare and commercial payer coverage policies, particularly regarding prior authorization requirements.
- Product Pipeline: Track progress of the CONVERT II pivotal trial for the AeriSeal System, which targets patients ineligible for Zephyr Valves.
- Management Transition: Evaluate the impact of the recent leadership changes (new CEO and CFO appointed in October 2025) on strategic execution.